Can avastin stop ovarian cancer from coming back?

NCT ID NCT02884648

Ongoing Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 2 times

Summary

This phase II trial tests whether the drug bevacizumab (Avastin) can help control ovarian, fallopian tube, or primary peritoneal cancer that is still present after initial treatment. About 35 women whose cancer was found during a second-look surgery will receive bevacizumab every three weeks. The main goal is to see how long the cancer stays under control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bevacizumab (Avastin)
What this could lead to: If it works, this could offer a way to delay or prevent the return of ovarian cancer after initial treatment.
What could go wrong: This is a small, early-phase trial with only 35 participants, so results may not apply widely. Bevacizumab can cause side effects like high blood pressure or bleeding.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPITHELIAL OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fallopian tube cancer fallopian tube neoplasm female reproductive organ cancer ovarian cancer ovarian carcinoma primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FALLOPIAN TUBE CANCER MALIGNANT NEOPLASMS OF FEMALE GENITAL ORGANS OVARIAN CANCER PRIMARY PERITONEAL CANCER

Contacts and locations

Locations

University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.